Profil
Yaping Shou worked as an Executive Medical Director at Millennium Pharmaceuticals, Inc. from 2011 to 2018, and as a Chief Medical Officer at Trillium Therapeutics ULC from 2018 to 2020.
Dr. Shou holds a doctorate degree from the University of Pennsylvania, Drexel University College of Medicine, and Zhejiang University School of Medicine.
Anciens postes connus de Yaping Shou
| Sociétés | Poste | Fin |
|---|---|---|
| TRILLIUM THERAPEUTICS | Chief Tech/Sci/R&D Officer | 02/11/2020 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01/06/2018 |
Formation de Yaping Shou
| University of Pennsylvania | Doctorate Degree |
| Drexel University College of Medicine | Doctorate Degree |
| Zhejiang University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
